Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma Specialty Channel

Cholangiocarcinoma
Specialty Channel
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
Allison Casey
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Stephanie Holland
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
01/19/2024
Allison Casey
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
Allison Casey
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
Allison Casey
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology

News

FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
Conference Coverage
Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma
05/28/2024
Allison Casey
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...
According to a phase 2 trial...
05/28/2024
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Stephanie Holland
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Conference Coverage
Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
01/19/2024
Allison Casey
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.
According to results from a...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
Janelle Bradley
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
Allison Casey
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology

Quiz
Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma
06/15/2023
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.
True or False: Patients with...
06/15/2023
Oncology
Quiz
Cholangioscopy for Diagnosis of Cholangiocarcinoma
06/15/2023
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.
When used to diagnose...
06/15/2023
Oncology
Quiz
Incidence of IDH Mutations in Cholangiocarcinoma
05/09/2023
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?
In what percentage of patients...
05/09/2023
Oncology
Quiz
Quiz: IDH Mutations in Biliary Tract Cancers
04/11/2023
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract cancer is more likely to be IDH-mutant?
Which type of biliary tract...
04/11/2023
Oncology
Quiz
Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma
12/01/2022
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...
How did the outcomes of patients...
12/01/2022
Oncology
Quiz
Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer
11/30/2022
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?
What was the approximate...
11/30/2022
Oncology
Quiz
Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
11/02/2022
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?
In the phase 2 FIDES-01 study,...
11/02/2022
Oncology
Test Your Knowledge
Quiz: What Test Can Be Used to Compare OS, DFS in ICC?
02/24/2022
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?
Which test can be used to...
02/24/2022
Oncology
Quiz
Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?
02/14/2022
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.
The FDA’s approval of...
02/14/2022
Oncology
Test Your Knowledge
Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology

Recent News

FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Neoadjuvant GOLP Demonstrates Efficacy, Safety in High-Risk Intrahepatic Cholangiocarcinoma
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Lirafugratinib Demonstrates Efficacy, Safety for Previously Treated Patients With FGFR2 Fusion-Positive Cholangiocarcinoma
01/13/2026
Stephanie Holland
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the phase 1/2...
01/13/2026
Oncology
News
Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors
05/17/2024
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...
Results from the ORANGE II PLUS...
05/17/2024
Oncology
News
Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer
11/02/2023
Allison Casey
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.
On November 1, 2023, the FDA...
11/02/2023
Oncology
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
07/20/2023
Allison Casey
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.
In a phase 2b study, zanidatamab...
07/20/2023
Oncology
News
Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit
11/21/2022
Allison Casey
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.
Among patients with primary...
11/21/2022
Oncology
News
Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers
11/10/2022
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.
In a phase 2 trial, trastuzumab...
11/10/2022
Oncology
News
Novel FGFR2 Inhibitor Shows Promise in Patients With Cholangiocarcinoma and an FGFR2-Fusion or Rearrangement
10/20/2022
Allison Casey
According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.
According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.
According to a phase 1/2 study,...
10/20/2022
Oncology
FDA Approval
FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma
05/08/2026
Stephanie Holland
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase...
05/08/2026
Oncology
News
Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma
05/07/2026
Stephanie Holland
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study...
05/07/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
FDA Alerts
Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer
05/07/2026
Stephanie Holland
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the...
05/07/2026
Oncology
News
Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer
05/07/2026
Emily Estrada
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.
Results from a retrospective...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology
News
Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
Combined results from the...
05/07/2026
Oncology
News
ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer
05/07/2026
Emily Estrada
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.
Exploratory ctDNA results from...
05/07/2026
Oncology
FDA Alerts
Capivasertib Gains Support from the FDA’s Advisory Committee in Metastatic Hormone-Sensitive Prostate Cancer
05/04/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase 3 CAPItello-281 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that capivasertib plus abiraterone and ADT demonstrates a favorable benefit-risk profile in PTEN-deficient metastatic...
Based on results from the phase...
05/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use